Kaerus Bioscience, a company focused on developing treatments for patients with rare genetic syndromes of neurodevelopment, has announced a technology access partnership with Neurolentech. Neurolentech is a startup that focuses on drug discovery for epilepsy and related genetic neurodevelopmental disorders (NDDs). This partnership allows Kaerus Bioscience to utilize Neurolentech’s NDD Drug Discovery platform, which includes proprietary cell models and assays for functional screens in neurodevelopmental disorders research.
The NDD Drug Discovery platform by Neurolentech consists of a wide range of human-derived neuronal cell lines from patients with various NDDs. This platform enables researchers to study the complex neural networks associated with genetic NDDs at a cellular level and explore the therapeutic potential of their small molecule pipeline for different genetic syndromes in preclinical studies.
This collaboration signifies a major advancement in Neurolentech’s efforts to enhance drug discovery for NDDs and solidifies the NDD Drug Discovery platform as a valuable resource for researchers and industry partners alike. CEO of Neurolentech, Fiona Nielsen, expressed excitement about the partnership and the unique insights their platform can offer in understanding disease mechanisms and developing new therapies. CEO of Kaerus Bioscience, Robert Ring, highlighted their commitment to using innovative technology and platform approaches to expedite the discovery of treatments for patients with genetic neurodevelopmental disorders.
